Differences Between Women and Men Taking a Combination of Indinavir, Ritonavir, Enteric-Coated Didanosine, and Stavudine Who Previously Took Anti-HIV Drugs
HIV Infections
About this trial
This is an interventional treatment trial for HIV Infections focused on measuring Didanosine, Drug Therapy, Combination, Stavudine, HIV Protease Inhibitors, Sex Factors, Ritonavir, Indinavir, Dosage Forms, Reverse Transcriptase Inhibitors, Anti-HIV Agents
Eligibility Criteria
Inclusion Criteria Patients may be eligible for this study if they: Are HIV-positive. Have viral load (amount of HIV in the blood) greater than 500 copies/ml. Have received anti-HIV treatment previously with an NNRTI plus an NRTI combination or only NRTIs for greater than 8 weeks and, if not currently on treatment, have been off treatment for 12 weeks or less. Failed to keep their viral load low during previous anti-HIV treatment. Are at least 18 years of age. Agree to use an effective barrier method of birth control. Exclusion Criteria Patients will not be eligible for this study if they: Have used a protease inhibitor for more than 14 days. Have used ddI or d4T for more than 30 days. Are pregnant or breast-feeding. Have an opportunistic (AIDS-related) infection requiring treatment at the time of enrollment. Have, or appear to have, peripheral neuropathy (a painful condition affecting the nervous system) at the time of screening. Are at risk for, or have had, pancreatitis (disease of the pancreas). Have difficulty absorbing medications. Have a cancer, other than Kaposi's sarcoma, that may require systemic treatment. Have any medical condition or treatment that may cause a rise in viral load. Have any other condition or previous treatment that would interfere with the study. Are unable to take drugs by mouth. Are receiving or have received recently any of the following drugs: terfenadine, astemizole, cisapride, triazolam, midazolam, ergot alkaloids, amiodarone, bepridil, flecainide, propafenone, quinidine, pimozide, rifampin, and intravenous (IV) pentamidine. Are receiving vincristine, thalidomide, foscarnet, or cisplatin or other medications that may cause nerve damage. Have received any experimental drug within 30 days prior to treatment. Are receiving treatment with testosterone, anabolic steroids, growth hormone, or megestrol acetate, except for certain hormonal problems.
Sites / Locations
- East Bay AIDS Ctr
- Univ of Southern California
- UCLA CARE Ctr
- North Broward Hosp District / HIV Clinical Research
- Saint Josephs Comprehensive Research Institute
- Louisiana State Univ Med Ctr / HIV Outpatient Clinic
- JSI Research and Training Institute
- Univ of Med & Dentistry of New Jersey
- Beth Israel Med Ctr
- Harlem Hosp Ctr
- Univ of Rochester Med Ctr
- Vanderbilt Univ School of Medicine
- Univ of Texas Southwestern Med Ctr
- Ponce Univ Hosp
- Univ of Puerto Rico School of Med